Zolmitriptan

How to order Zolmitriptan

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Zolmitriptan on Prescriptsy

Zolmitriptan is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Zolmitriptan is a selective serotonin (5-HT1B/1D) receptor agonist belonging to the triptan class, used for the acute treatment of migraine attacks with or without aura in adults.

It is available in 3 formulations: conventional tablets (2.5 mg), orodispersible tablets (2.5 mg, dissolving on the tongue without water), and a nasal spray (5 mg per actuation).

The availability of multiple formulations makes zolmitriptan particularly versatile for patients who experience nausea and vomiting during attacks. Zolmitriptan is a prescription-only medicine (POM) in the United Kingdom.

Migraine is the third most prevalent medical condition in the world and the leading cause of disability in people under 50 years of age.

In the UK, approximately 1 in 7 adults (over 10 million people) experience migraine, with women affected 3 times more commonly than men.

Migraine attacks cause moderate to severe throbbing headache (typically unilateral), nausea and vomiting, photophobia (light sensitivity), phonophobia (sound sensitivity), and functional disability lasting 4 to 72 hours if untreated.

The economic burden is substantial, with migraine estimated to account for 25 million lost working days per year in the UK.

This page provides a comprehensive clinical guide to zolmitriptan, covering its mechanism of action, formulations, dosage, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about zolmitriptan

Before reading further, note these essential safety points about zolmitriptan.

• Zolmitriptan is contraindicated in patients with ischaemic heart disease, previous stroke, peripheral vascular disease, or uncontrolled hypertension.
• Do not take zolmitriptan within 24 hours of another triptan or ergotamine-containing medication.
• Limit use to no more than 10 days per month to avoid medication overuse headache.
• Chest tightness and pressure sensations are a recognised class effect and do not usually indicate cardiac problems, but severe or persistent chest pain should be investigated.
• If the first dose does not relieve the headache, do not take a second dose for the same attack.

Understanding migraine pathophysiology

Migraine is a complex neurological disorder involving genetic susceptibility, cortical hyperexcitability, and activation of the trigeminovascular system.

The current understanding recognises migraine as a brain disorder, not simply a vascular headache. The migraine attack progresses through distinct phases.

The premonitory (prodromal) phase involves hypothalamic and brainstem activation, producing symptoms such as yawning, food cravings, mood changes, and neck stiffness hours to days before the headache.

The aura phase (present in approximately 25 to 30% of migraineurs) is caused by cortical spreading depression (CSD), a wave of neuronal depolarisation followed by suppression spreading across the cortex at 2 to 6 mm/min, producing transient neurological symptoms (visual disturbance, sensory changes, speech difficulty) lasting 5 to 60 minutes.

The headache phase results from activation of the trigeminovascular system.

Trigeminal sensory nerve fibres (originating from the trigeminal ganglion and innervating the meninges and intracranial blood vessels) release vasoactive neuropeptides, principally calcitonin gene-related peptide (CGRP), substance P, and neurokinin A.

CGRP causes potent vasodilation of meningeal blood vessels, promotes neurogenic inflammation (plasma protein extravasation, mast cell degranulation), and sensitises the trigeminal nociceptive pathway.

Pain signals are transmitted via the trigeminal nerve to the trigeminal nucleus caudalis in the brainstem, then to the thalamus and cortical pain-processing regions.

Peripheral and central sensitisation develops during prolonged attacks, leading to cutaneous allodynia (pain from normally non-painful stimuli such as touching the scalp or wearing glasses).

How zolmitriptan works

Zolmitriptan acts through 3 complementary mechanisms targeting different sites in the trigeminovascular pathway.

First, it activates 5-HT1B receptors on meningeal and cerebral blood vessels, causing selective cranial vasoconstriction that reverses the pathological vasodilation triggered by CGRP release.

This vasoconstriction is specific to cranial vessels and does not significantly affect systemic blood pressure at therapeutic doses.

Second, it activates presynaptic 5-HT1D receptors on trigeminal nerve terminals, inhibiting the release of CGRP, substance P, and other pro-inflammatory neuropeptides, thereby reducing neurogenic inflammation.

Third, it inhibits pain signal transmission in the trigeminal nucleus caudalis in the brainstem, reducing central nociceptive processing.

The 5-HT1B receptor mediates the vasoconstrictive effect, which is why triptans are contraindicated in cardiovascular disease (they can theoretically constrict coronary arteries).

The 5-HT1D and 5-HT1F receptor mechanisms are non-vasoconstrictive and are primarily responsible for the anti-migraine effect through modulation of neurotransmitter release and central pain processing.

Zolmitriptan formulations

Conventional tablets (2.5 mg)

Swallowed whole with water. Absorbed from the gastrointestinal tract with approximately 40% bioavailability. Peak plasma concentration at 1 to 1.5 hours. Suitable for patients without significant nausea or vomiting.

Orodispersible tablets (2.5 mg)

Placed on the tongue, dissolving within seconds and swallowed with saliva.

No water required, making them convenient during an attack when water may not be available or when nausea makes swallowing difficult.

Bioavailability is similar to conventional tablets (the drug is absorbed from the GI tract, not from the oral mucosa). Peak plasma concentration at approximately 3 hours.

The convenience and discretion of this formulation are its main advantages.

Nasal spray (5 mg)

Delivered directly into the nasal cavity.

Approximately 30% of the dose is absorbed directly across the nasal mucosa (bypassing first-pass hepatic metabolism), with the remainder swallowed and absorbed from the GI tract.

Peak plasma concentration occurs earlier (15 minutes to 1 hour) and some patients experience faster headache relief compared with oral formulations.

The nasal spray is particularly valuable for patients with severe nausea or vomiting, or gastric stasis (delayed gastric emptying, which commonly occurs during migraine and impairs oral drug absorption).

The main drawback is an unpleasant bitter taste, reported by approximately 20% of patients.

Comparison with other triptans

Seven triptans are available in the UK: sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan.

They share the same mechanism of action but differ in pharmacokinetic profile (speed of onset, duration of action), formulation availability, and individual patient response.

Sumatriptan is the most widely used and is available as a pharmacy medicine (50 mg tablets) without prescription.

Zolmitriptan is distinguished by its availability in 3 formulations (tablet, orodispersible, nasal spray), giving it the widest range of delivery options.

Eletriptan has the highest 2-hour response rate in comparative trials. Frovatriptan has the longest half-life (26 hours) and is sometimes used for menstrual migraine prophylaxis.

Individual response to triptans varies, and failure to respond to one triptan does not predict failure with another.

NICE guideline CG150 on headaches recommends offering a triptan alongside a non-steroidal anti-inflammatory drug (NSAID) or paracetamol as acute treatment for migraine.

Dosage and administration

Tablets: 2.5 mg at onset of headache. If headache recurs, repeat after at least 2 hours. Maximum 10 mg in 24 hours.

Nasal spray: 5 mg into one nostril. If headache recurs, repeat after at least 2 hours. Maximum 10 mg in 24 hours.

If no relief from the first dose, do not repeat for the same attack. Dose reduction is required in moderate to severe hepatic impairment and with CYP1A2 inhibitors.

Take at the onset of the headache phase, not during the aura.

Side effects of zolmitriptan

Common side effects

Taste disturbance (bitter taste, especially with nasal spray), tingling and numbness (paraesthesia), warm sensations, triptan sensations (chest tightness, throat pressure, jaw discomfort, heaviness), dizziness, drowsiness, nausea, dry mouth, and muscle weakness.

Triptan sensations are not cardiac in origin but can be alarming; patients should be counselled about this class effect before first use.

Uncommon and rare side effects

Palpitations, tachycardia, and transient blood pressure elevation are uncommon. Coronary vasospasm, myocardial infarction, and cardiac arrhythmias are extremely rare but underpin the cardiovascular contraindications.

Serotonin syndrome is rare, primarily when combined with serotonergic drugs. Medication overuse headache develops with use exceeding 10 days per month for 3 or more months.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Zolmitriptan is contraindicated in ischaemic heart disease, previous stroke or TIA, peripheral vascular disease, Wolff-Parkinson-White syndrome, uncontrolled hypertension, moderate or severe hepatic impairment (nasal spray), hemiplegic or basilar migraine, concurrent or recent (24 hours) use of other triptans or ergotamine, and use within 2 weeks of an MAOI.

Cardiovascular risk assessment is required before prescribing. Limit use to 10 days per month. Pregnancy: avoid unless clearly necessary. Breastfeeding: avoid for 24 hours after a dose.

Managing migraine beyond acute treatment

Effective migraine management extends beyond acute treatment with triptans.

The BASH (British Association for the Study of Headache) guidelines recommend a comprehensive approach incorporating trigger identification and avoidance (common triggers include stress, sleep disruption, missed meals, dehydration, hormonal changes, specific foods, weather changes, and bright or flickering lights), regular lifestyle habits (consistent sleep schedule, regular meals, adequate hydration, and regular moderate exercise), a headache diary (recording attack frequency, severity, triggers, medication use, and response to treatment), and preventive medication when attacks occur 4 or more times per month or cause significant disability despite optimal acute treatment.

NICE-recommended preventive medications include propranolol 40 to 240 mg daily (a non-selective beta-blocker, first-line for many patients), amitriptyline 10 to 50 mg at night (a tricyclic antidepressant with evidence for migraine prevention, particularly useful for co-existing tension-type headache or sleep disturbance), topiramate 50 to 100 mg daily (an anticonvulsant, effective but associated with cognitive side effects and contraindicated in pregnancy), and candesartan 8 to 16 mg daily (an angiotensin receptor blocker, well-tolerated alternative).

For patients failing 3 or more conventional preventives, CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) are available through specialist headache services (NICE TA764).

How to get zolmitriptan in the UK

Zolmitriptan is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

It is available as generic zolmitriptan (tablets and orodispersible tablets) and as the branded nasal spray Zomig Nasal Spray.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Sources

• Zolmitriptan 2.5 mg Tablets, Summary of Product Characteristics (EMC)
• Zolmitriptan, British National Formulary (BNF)
• NICE CG150: Headaches in over 12s: diagnosis and management
• Migraine, NICE CKS
• Migraine, NHS
• MHRA Yellow Card Scheme